© 2019 IPHARMA

  • Facebook Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon

IPHARMA was authorized by the Ministry of Healthcare to conduct the Phase I clinical trial of the medicinal product XC125

27.04.2016

On 25th of April, 2016, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase I clinical trial of the medicinal product XC125.

 

Protocol № ARI-XC125-01 "Double-blind randomized placebo-controlled clinical study of safety, tolerability, pharmacokinetics and pharmacodynamics of rising doses of XC125 for single and multiple oral use in healthy subjects".

 

The purpose of this clinical trial is to study safety, tolerability, pharmacokinetics and pharmacodynamics of rising doses of the study drug.

 

The area of the study drug XC125 use – infectious diseases.

 

IPHARMA has a large experience in conducting Phase I-III studies in this therapeutic area. The company specialists will manage monitoring, data collecting and processing, medical expertise and study report preparation in accordance with international standards.

 

 

Please reload

Недавние посты
Please reload

Архив
Please reload